Financials data is unavailable for this security.
View more
Year on year Sunshine Biopharma Inc grew revenues 454.42% from 4.35m to 24.09m while net income improved from a loss of 26.74m to a smaller loss of 4.51m.
Gross margin | 30.41% |
---|---|
Net profit margin | -12.07% |
Operating margin | -15.20% |
Return on assets | -12.75% |
---|---|
Return on equity | -15.80% |
Return on investment | -15.41% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Sunshine Biopharma Inc fell by 5.53m. Cash Flow from Financing totalled 3.43m or 14.22% of revenues. In addition the company used 8.78m for operations while cash used for investing totalled 656.15k.
Cash flow per share | -117.09 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 20.07 |
---|---|
Tangible book value per share | 17.98 |
More ▼
Balance sheet in USDView more
Current ratio | 4.86 |
---|---|
Quick ratio | 3.26 |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼